{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,31]],"date-time":"2025-08-31T10:12:06Z","timestamp":1756635126003,"version":"3.41.0"},"reference-count":49,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2016,6,1]],"date-time":"2016-06-01T00:00:00Z","timestamp":1464739200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2016,6]]},"DOI":"10.1016\/j.clinthera.2016.03.028","type":"journal-article","created":{"date-parts":[[2016,4,29]],"date-time":"2016-04-29T10:29:15Z","timestamp":1461925755000},"page":"1417-1434.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus"],"prefix":"10.1016","volume":"38","clinical-trial-number":[{"clinical-trial-number":"nct00641225","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct00714116","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Stanley","family":"Cohen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Megan","family":"Clowse","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Pardo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Indranil","family":"Bhattacharya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandeep","family":"Menon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Gourley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annette","family":"Diehl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2016.03.028_bib1","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1016\/S0140-6736(01)06075-5","article-title":"Rheumatoid arthritis","volume":"358","author":"Lee","year":"2001","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2016.03.028_bib2","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1056\/NEJMra071297","article-title":"Systemic lupus erythematosus","volume":"358","author":"Rahman","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clinthera.2016.03.028_bib3","series-title":"Primer on the Rheumatic Disease","first-page":"114","article-title":"Rheumatoid arthritis","author":"Tehlirian","year":"2008"},{"key":"10.1016\/j.clinthera.2016.03.028_bib4","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4140\/TCP.n.2013.110","article-title":"Systemic lupus erythematosus: a review of the disease and treatment options","volume":"28","author":"Gurevitz","year":"2013","journal-title":"Consult Pharm"},{"key":"10.1016\/j.clinthera.2016.03.028_bib5","first-page":"182","article-title":"B cell biology and dysfunction in SLE","volume":"65","author":"Anolik","year":"2007","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib6","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.autrev.2011.06.010","article-title":"B cells and their targeting in rheumatoid arthritis\u2014current concepts and future perspectives","volume":"11","author":"Nakken","year":"2011","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.clinthera.2016.03.028_bib7","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pr.109.002006","article-title":"Therapeutic targeting of B cells for rheumatic autoimmune diseases","volume":"63","author":"Engel","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.clinthera.2016.03.028_bib8","doi-asserted-by":"crossref","first-page":"3823","DOI":"10.1016\/j.molimm.2007.06.151","article-title":"Mechanisms of killing by anti-CD20 monoclonal antibodies","volume":"44","author":"Glennie","year":"2007","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib9","first-page":"200","article-title":"B-cell therapies for rheumatoid arthritis","volume":"70","author":"Scher","year":"2012","journal-title":"Bull NYU Hosp Jt Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib10","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1136\/ard.2011.151522","article-title":"Ofatumumab, a fully human anti-CD20 monoclonal antibody, in biological-naive, rheumatoid arthritis patients with an inadequate response to methotrexate: a randomised, double-blind, placebo-controlled clinical trial","volume":"70","author":"Taylor","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib11","doi-asserted-by":"crossref","first-page":"2783","DOI":"10.1002\/art.38107","article-title":"Rituximab-induced T cell depletion in patients with rheumatoid arthritis: association with clinical response","volume":"65","author":"Melet","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib12","doi-asserted-by":"crossref","first-page":"14","DOI":"10.4161\/mabs.2.1.10789","article-title":"Evolution of anti-CD20 monoclonal antibody therapeutics in oncology","volume":"2","author":"Oflazoglu","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.clinthera.2016.03.028_bib13","doi-asserted-by":"crossref","first-page":"1256","DOI":"10.1177\/0961203310373107","article-title":"Three different B-cell depletion (anti-CD20 monoclonal antibodies) treatments for severe resistant systemic lupus erythematosus","volume":"19","author":"Faria","year":"2010","journal-title":"Lupus"},{"key":"10.1016\/j.clinthera.2016.03.028_bib14","unstructured":"A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus (EXPLORER). ClinicalTrials.gov; 2015. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00137969?term=rituximab+and+SLE&rank=1. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib15","unstructured":"Efficacy Supplement Approvals in 2006: Rituximab. US Food and Drug Administration; 2006. http:\/\/www.fda.gov\/drugs\/developmentapprovalprocess\/howdrugsaredevelopedandapproved\/drugandbiologicapprovalreports\/ucm081895.htm. Accessed May 1, 2015."},{"issue":"Suppl 2","key":"10.1016\/j.clinthera.2016.03.028_bib16","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.62.suppl_2.ii55","article-title":"B cell therapy for rheumatoid arthritis: the rituximab (anti-CD20) experience","volume":"62","author":"Shaw","year":"2003","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib17","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4161\/mabs.2.1.10786","article-title":"Antibody fragments: hope and hype","volume":"2","author":"Nelson","year":"2010","journal-title":"MAbs"},{"key":"10.1016\/j.clinthera.2016.03.028_bib18","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1016\/j.clinthera.2008.10.017","article-title":"Pharmacokinetic and pharmacodynamic properties of TRU-015, a CD20-directed small modular immunopharmaceutical protein therapeutic, in patients with rheumatoid arthritis: a Phase I, open-label, dose-escalation clinical study","volume":"30","author":"Burge","year":"2008","journal-title":"Clin Ther"},{"key":"10.1016\/j.clinthera.2016.03.028_bib19","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1093\/rheumatology\/keq423","article-title":"Distinct in vitro binding properties of the anti-CD20 small modular immunopharmaceutical 2LM20-4 result in profound and sustained in vivo potency in cynomolgus monkeys","volume":"50","author":"Nickerson-Nutter","year":"2011","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.clinthera.2016.03.028_bib20","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/art.1780310302","article-title":"The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis","volume":"31","author":"Arnett","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib21","doi-asserted-by":"crossref","first-page":"1725","DOI":"10.1002\/art.1780400928","article-title":"Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus","volume":"40","author":"Hochberg","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib22","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1002\/art.1780251101","article-title":"The 1982 revised criteria for the classification of systemic lupus erythematosus","volume":"25","author":"Tan","year":"1982","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib23","doi-asserted-by":"crossref","first-page":"633","DOI":"10.2165\/11535960-000000000-00000","article-title":"Population pharmacokinetics of therapeutic monoclonal antibodies","volume":"49","author":"Dirks","year":"2010","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.clinthera.2016.03.028_bib24","unstructured":"Rituxan (rituximab) [prescribing information]. 2014. http:\/\/www.gene.com\/download\/pdf\/rituxan_prescribing.pdf. Accessed January 29, 2016."},{"key":"10.1016\/j.clinthera.2016.03.028_bib25","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1002\/art.21778","article-title":"The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trial","volume":"54","author":"Emery","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib26","first-page":"190","article-title":"Kinetics of B cell depletion and reconstitution in peripheral blood and lymphoid tissues after single dose of SBI-087, a humanized anti-CD20 SMIP, in cynomolgus monkeys","volume":"61","author":"Danussi-Joannopoulos","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib27","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1002\/art.22025","article-title":"Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib28","first-page":"1206","article-title":"Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies","volume":"9","author":"Hutas","year":"2008","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1016\/j.clinthera.2016.03.028_bib29","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1136\/annrheumdis-2011-200706","article-title":"Safety and efficacy of ocrelizumab in combination with methotrexate in MTX-naive subjects with rheumatoid arthritis: the phase III FILM trial","volume":"71","author":"Stohl","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.clinthera.2016.03.028_bib30","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1002\/art.33353","article-title":"Safety and efficacy of ocrelizumab in patients with rheumatoid arthritis and an inadequate response to at least one tumor necrosis factor inhibitor: results of a forty-eight-week randomized, double-blind, placebo-controlled, parallel-group phase III trial","volume":"64","author":"Tak","year":"2012","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib31","unstructured":"A Study To Evaluate Two Doses of Ocrelizumab in Patients With Active Systemic Lupus Erythematosus (BEGIN). ClinicalTrials.gov; 2013. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00539838?term=ocrelizumab+AND+SLE&rank=1. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib32","unstructured":"A Study To Evaluate Ocrelizumab in Combination With Methotrexate Compared With Infliximab Plus Methotrexate in Patients With Active Rheumatoid Arthritis Currently Responding Inadequately to Etanercept or Adalimumab. ClinicalTrials.gov; 2015. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00808210?term=ocrelizumab+AND+RA&rank=2. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib33","unstructured":"A Study To Evaluate Ocrelizumab Compared With Placebo in Patients With Rheumatoid Arthritis Who Have an Inadequate Response to Methotrexate Therapy (FEATURE). ClinicalTrials.gov; 2013. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00673920?term=Ocrelizumab+AND+RA&rank=3. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib34","unstructured":"VELVET, a Dose Range Finding Trial of Veltuzumab in Subjects With Moderate to Severe Rheumatoid Arthritis. ClinicalTrials.gov; 2012. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT01390545?term=Veltuzumab&rank=5. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib35","unstructured":"Investigating Clinical Efficacy of Ofatumumab in Adult Rheumatoid Arthritis (RA) Patients Who Had an Inadequate Response to TNF-\u03b1 Antagonist Therapy. ClinicalTrials.gov; 2014. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT00603525?term=NCT00603525&rank=1. Accessed May 1, 2015."},{"key":"10.1016\/j.clinthera.2016.03.028_bib36","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1177\/0091270007305297","article-title":"Rituximab pharmacokinetics in patients with rheumatoid arthritis: B-cell levels do not correlate with clinical response","volume":"47","author":"Breedveld","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib37","doi-asserted-by":"crossref","first-page":"2645","DOI":"10.1002\/jps.20178","article-title":"Antibody pharmacokinetics and pharmacodynamics","volume":"93","author":"Lobo","year":"2004","journal-title":"J Pharm Sci"},{"key":"10.1016\/j.clinthera.2016.03.028_bib38","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1038\/clpt.2008.170","article-title":"Monoclonal antibody pharmacokinetics and pharmacodynamics","volume":"84","author":"Wang","year":"2008","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.clinthera.2016.03.028_bib39","doi-asserted-by":"crossref","first-page":"1104","DOI":"10.1177\/0091270007306958","article-title":"Pharmacokinetic drug-drug interaction potentials for therapeutic monoclonal antibodies: reality check","volume":"47","author":"Seitz","year":"2007","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib40","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1146\/annurev-pharmtox-010510-100510","article-title":"Mechanisms of monoclonal antibody-drug interactions","volume":"51","author":"Zhou","year":"2011","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib41","doi-asserted-by":"crossref","first-page":"2580","DOI":"10.1002\/art.20430","article-title":"B cell depletion as a novel treatment for systemic lupus erythematosus: a phase I\/II dose-escalation trial of rituximab","volume":"50","author":"Looney","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib42","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.4049\/jimmunol.179.5.3351","article-title":"Depletion of B cells in murine lupus: efficacy and resistance","volume":"179","author":"Ahuja","year":"2007","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib43","doi-asserted-by":"crossref","first-page":"3888","DOI":"10.4049\/jimmunol.1101629","article-title":"An acquired defect in IgG-dependent phagocytosis explains the impairment in antibody-mediated cellular depletion in Lupus","volume":"187","author":"Ahuja","year":"2011","journal-title":"J Immunol"},{"key":"10.1016\/j.clinthera.2016.03.028_bib44","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/art.10764","article-title":"The relationship of FcgammaRIIIa genotype to degree of B cell depletion by rituximab in the treatment of systemic lupus erythematosus","volume":"48","author":"Anolik","year":"2003","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib45","doi-asserted-by":"crossref","first-page":"2546","DOI":"10.2741\/2254","article-title":"B cell depletion therapy in autoimmune diseases","volume":"12","author":"Sanz","year":"2007","journal-title":"Front Biosci"},{"key":"10.1016\/j.clinthera.2016.03.028_bib46","doi-asserted-by":"crossref","first-page":"2993","DOI":"10.1002\/art.23902","article-title":"Highly sensitive B cell analysis predicts response to rituximab therapy in rheumatoid arthritis","volume":"58","author":"Dass","year":"2008","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.clinthera.2016.03.028_bib47","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1136\/annrheumdis-2013-204544","article-title":"An extra dose of rituximab improves clinical response in rheumatoid arthritis patients with initial incomplete B cell depletion: a randomised controlled trial","volume":"74","author":"Vital","year":"2015","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 1","key":"10.1016\/j.clinthera.2016.03.028_bib48","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1186\/ar3910","article-title":"B-cell depletion in SLE: clinical and trial experience with rituximab and ocrelizumab and implications for study design","volume":"15","author":"Reddy","year":"2013","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.clinthera.2016.03.028_bib49","doi-asserted-by":"crossref","first-page":"3038","DOI":"10.1002\/art.30466","article-title":"B cell biomarkers of rituximab responses in systemic lupus erythematosus","volume":"63","author":"Vital","year":"2011","journal-title":"Arthritis Rheum"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301655?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291816301655?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T22:52:40Z","timestamp":1748904760000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291816301655"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,6]]},"references-count":49,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,6]]}},"alternative-id":["S0149291816301655"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.028","relation":{},"ISSN":["0149-2918"],"issn-type":[{"type":"print","value":"0149-2918"}],"subject":[],"published":{"date-parts":[[2016,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety, Tolerability, Pharmacokinetic and Pharmacodynamic Properties of SBI-087, a CD20-Directed B-cell Depleting Agent: Phase 1 Dose Escalating Studies in Patients With Either Mild Rheumatoid Arthritis or Systemic Lupus","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2016.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}